Covid-19: Remdesivir is recommended for authorisation by European Medicines Agency

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use

This should be read in conjunction with the " Question and Answer " document on the withdrawal of the application: the Assessment Report may not include all available information on the product if the CHMP assessment of the latest submitted information was still ongoing at the time of the withdrawal of the application.

European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use

DISCUSSION IN THE EFFICACY WORKING PARTY (EWP) May 1998/ January 2000 TRANSMISSION TO CPMP November 2000 RELEASE FOR CONSULTATION November 2000 DEADLINE FOR COMMENTS February 2001 DISCUSSION IN THE EFFICACY WORKING PARTY June 2001 TRANSMISSION TO CPMP November 2001 ADOPTION BY CPMP November 2001 DRAFT REV. 1 AGREED BY EFFICACY WORKING PARTY April 2008 ADOPTION BY CHMP FOR RELEASE FOR CONSULTATI...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use

European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use

European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use